<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; From</title>
	<atom:link href="http://www.tapanray.in/tag/from/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Trees Die From The Top: Apt For Pharma Leadership Too?</title>
		<link>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=trees-die-from-the-top-apt-for-pharma-leadership-too</link>
		<comments>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/#comments</comments>
		<pubDate>Mon, 22 Oct 2018 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[appraisal]]></category>
		<category><![CDATA[apt]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[dies]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[metric]]></category>
		<category><![CDATA[Narasimhan]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[Tree]]></category>
		<category><![CDATA[Vas]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9229</guid>
		<description><![CDATA[The Management Guru of all-time &#8211; Peter F. Drucker once said: &#8220;The spirit of an organization is created from the top… If an organization is great in spirit, it is because the spirit of its top people is great.” As &#8230; <a href="http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nine Major Challenges Constraining Indian Pharmaceutical Industry From Taking a Quantum Leap</title>
		<link>http://www.tapanray.in/nine-major-challenges-constraining-indian-pharmaceutical-industry-from-taking-a-quantum-leap/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nine-major-challenges-constraining-indian-pharmaceutical-industry-from-taking-a-quantum-leap</link>
		<comments>http://www.tapanray.in/nine-major-challenges-constraining-indian-pharmaceutical-industry-from-taking-a-quantum-leap/#comments</comments>
		<pubDate>Mon, 01 Oct 2012 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Constraining]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[Nine]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Quantum]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Taking]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1087</guid>
		<description><![CDATA[Among the developing nations of the world, India has already carved out a special niche for itself in many business verticals of the pharmaceutical industry and is currently being recognized as the ‘pharmacy of the world’ for the generic medicines. &#8230; <a href="http://www.tapanray.in/nine-major-challenges-constraining-indian-pharmaceutical-industry-from-taking-a-quantum-leap/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nine-major-challenges-constraining-indian-pharmaceutical-industry-from-taking-a-quantum-leap/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping rich harvest with less moaning and bagful of creative ideas from emerging Rural Markets of India</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/#comments</comments>
		<pubDate>Mon, 07 May 2012 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[bagful]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[harvest]]></category>
		<category><![CDATA[ideas]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[janaaushadhi]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[moaning]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=97</guid>
		<description><![CDATA[About 72 percent of the population and 135 million households of India live in the rural areas of the country. Many of them are poor. Definition of &#8216;Rural&#8217;: Agencies of the Government of India like, National Council of Applied Economic &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare Industry of India: Being catapulted from a labyrinth to an accelerated growth trajectory</title>
		<link>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory</link>
		<comments>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/#comments</comments>
		<pubDate>Mon, 12 Mar 2012 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerated]]></category>
		<category><![CDATA[Being]]></category>
		<category><![CDATA[catapulted]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[labyrinth]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trajectory]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=122</guid>
		<description><![CDATA[As reported by the &#8216;World Health Statistics 2011&#8242;, India spends around 4.2 percent of its Gross Domestic Product (GDP) on health, which is quite comparable with other BRIC countries like, China and Russia.This has been possible mainly due to increasing &#8230; <a href="http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-industry-of-india-being-catapulted-from-a-labyrinth-to-an-accelerated-growth-trajectory/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game Changer: Effective transition from ‘blockbuster’ to an integrated ‘niche buster’ plus &#8216;generic drugs&#8217; business model</title>
		<link>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model</link>
		<comments>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/#comments</comments>
		<pubDate>Sun, 20 Nov 2011 07:58:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[buster]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[drugs. business]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[integrated]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[niche]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=172</guid>
		<description><![CDATA[Since quite some time global pharmaceutical majors have been operating within the confines of high risk &#8211; high reward R&#38;D based business model with blockbuster drugs (annual sales of over US$ 1 billion). Blockbuster brands, mostly in the chronic-care segments &#8230; <a href="http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Family owned pharma business: Separate ownership from management for long term organization interest</title>
		<link>http://www.tapanray.in/family-owned-pharma-business-separate-ownership-from-management-for-long-term-organization-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=family-owned-pharma-business-separate-ownership-from-management-for-long-term-organization-interest</link>
		<comments>http://www.tapanray.in/family-owned-pharma-business-separate-ownership-from-management-for-long-term-organization-interest/#comments</comments>
		<pubDate>Mon, 22 Aug 2011 00:30:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Family]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[owned]]></category>
		<category><![CDATA[ownership]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Separate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[term]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=212</guid>
		<description><![CDATA[A study recently conducted by &#8216;ASK Investment Managers&#8217; reported, &#8220;Family Owned Businesses (FOB)&#8221; account for 60% of market cap among the top 500 companies in India and comprise 17% of the IT Industry, 10% of refineries, 7% of automobiles and &#8230; <a href="http://www.tapanray.in/family-owned-pharma-business-separate-ownership-from-management-for-long-term-organization-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/family-owned-pharma-business-separate-ownership-from-management-for-long-term-organization-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create, Deliver and Realize maximum value from a new product launch with an innovative Supply Chain Management system</title>
		<link>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system</link>
		<comments>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/#comments</comments>
		<pubDate>Mon, 30 Aug 2010 01:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximum]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Realize]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=381</guid>
		<description><![CDATA[Like in many other industries, effective supply-chain management (SCM) in the pharmaceutical industry involves a systematic process, spanning from procurement of raw, packaging and other related materials, converting those materials into finished goods stock keeping units (SKUs), inventory management of &#8230; <a href="http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The top 10 environment polluters of the world should now transform themselves into the top 10 saviours of the world from the disaster of Climate Change</title>
		<link>http://www.tapanray.in/the-top-10-environment-polluters-of-the-world-should-now-transform-themselves-into-the-top-10-saviours-of-the-world-from-the-disaster-of-climate-change/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-top-10-environment-polluters-of-the-world-should-now-transform-themselves-into-the-top-10-saviours-of-the-world-from-the-disaster-of-climate-change</link>
		<comments>http://www.tapanray.in/the-top-10-environment-polluters-of-the-world-should-now-transform-themselves-into-the-top-10-saviours-of-the-world-from-the-disaster-of-climate-change/#comments</comments>
		<pubDate>Thu, 24 Dec 2009 00:30:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[disaster]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[into the]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[polluters]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[saviours]]></category>
		<category><![CDATA[Should]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[themselves]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[transform]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=688</guid>
		<description><![CDATA[Global awareness dawned early: After World War the second, various types of atmospheric pollution started drawing increasing public attention in the western world, both in the USA and Europe. In Europe, the incidence of London’s ‘Great Smog’ in 1952 initiated the process &#8230; <a href="http://www.tapanray.in/the-top-10-environment-polluters-of-the-world-should-now-transform-themselves-into-the-top-10-saviours-of-the-world-from-the-disaster-of-climate-change/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-top-10-environment-polluters-of-the-world-should-now-transform-themselves-into-the-top-10-saviours-of-the-world-from-the-disaster-of-climate-change/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Open Source Drug Discovery (OSDD) initiative for the tropical diseases by CSIR and cancer by GlaxoSmithKline deserves a big applaud and support from all concerned.</title>
		<link>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned</link>
		<comments>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/#comments</comments>
		<pubDate>Thu, 03 Dec 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[applaud]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[concerned]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[deserves]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool. Open]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[tropical]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=709</guid>
		<description><![CDATA[As the name suggest the ‘Open Source Drug Discovery (OSDD)’ is an open source code model of discovering a New Chemical Entity (NCE) or a New Molecular Entity (NME). In this model all data generated related to the discovery research will be &#8230; <a href="http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To prevent ‘counterfeit medicines’ from reaching the patients is the nation&#8217;s public health responsibility: Are we still in a denial mode to even accept the existence of this public health menace?</title>
		<link>http://www.tapanray.in/to-prevent-counterfeit-medicines-from-reaching-the-patients-is-the-nations-public-health-responsibility-are-we-still-in-a-denial-mode-to-even-accept-the-existence-of-this-public-h/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-prevent-counterfeit-medicines-from-reaching-the-patients-is-the-nations-public-health-responsibility-are-we-still-in-a-denial-mode-to-even-accept-the-existence-of-this-public-h</link>
		<comments>http://www.tapanray.in/to-prevent-counterfeit-medicines-from-reaching-the-patients-is-the-nations-public-health-responsibility-are-we-still-in-a-denial-mode-to-even-accept-the-existence-of-this-public-h/#comments</comments>
		<pubDate>Thu, 19 Nov 2009 01:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[accept]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[denial]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[existence]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prevent]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reaching]]></category>
		<category><![CDATA[responsibility]]></category>
		<category><![CDATA[still]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[this]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=721</guid>
		<description><![CDATA[In November 7, 2009, Financial Express reported with a headline,”Generic drug companies see a bitter pill in counterfeit&#8220;, because some believe that it has an in-built intellectual property right connotation. The dictionary definition: The word ‘counterfeit’ may be defined as &#8230; <a href="http://www.tapanray.in/to-prevent-counterfeit-medicines-from-reaching-the-patients-is-the-nations-public-health-responsibility-are-we-still-in-a-denial-mode-to-even-accept-the-existence-of-this-public-h/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-prevent-counterfeit-medicines-from-reaching-the-patients-is-the-nations-public-health-responsibility-are-we-still-in-a-denial-mode-to-even-accept-the-existence-of-this-public-h/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
